AU2018249310A1 - Treatment of inflammatory diseases with inhibitors of C5a activity - Google Patents
Treatment of inflammatory diseases with inhibitors of C5a activity Download PDFInfo
- Publication number
- AU2018249310A1 AU2018249310A1 AU2018249310A AU2018249310A AU2018249310A1 AU 2018249310 A1 AU2018249310 A1 AU 2018249310A1 AU 2018249310 A AU2018249310 A AU 2018249310A AU 2018249310 A AU2018249310 A AU 2018249310A AU 2018249310 A1 AU2018249310 A1 AU 2018249310A1
- Authority
- AU
- Australia
- Prior art keywords
- antibody
- antigen
- binding
- compound
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17164573 | 2017-04-03 | ||
| EP17164573.2 | 2017-04-03 | ||
| EP17177657 | 2017-06-23 | ||
| EP17177657.8 | 2017-06-23 | ||
| EP17189938.8 | 2017-09-07 | ||
| EP17189938 | 2017-09-07 | ||
| PCT/EP2018/050146 WO2018184739A1 (en) | 2017-04-03 | 2018-01-03 | Treatment of inflammatory diseases with inhibitors of c5a activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2018249310A1 true AU2018249310A1 (en) | 2019-10-17 |
Family
ID=61024731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018249310A Abandoned AU2018249310A1 (en) | 2017-04-03 | 2018-01-03 | Treatment of inflammatory diseases with inhibitors of C5a activity |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US10376595B2 (https=) |
| EP (3) | EP3978523A1 (https=) |
| JP (2) | JP7486415B2 (https=) |
| KR (1) | KR20190138806A (https=) |
| CN (1) | CN111108118A (https=) |
| AU (1) | AU2018249310A1 (https=) |
| CA (1) | CA3058023A1 (https=) |
| CL (1) | CL2018002698A1 (https=) |
| DK (1) | DK3411400T3 (https=) |
| ES (1) | ES2893769T3 (https=) |
| IL (1) | IL261809B2 (https=) |
| MX (1) | MX2019011825A (https=) |
| PL (1) | PL3411400T3 (https=) |
| SG (1) | SG11201807998WA (https=) |
| TW (2) | TWI826364B (https=) |
| WO (1) | WO2018184739A1 (https=) |
| ZA (1) | ZA201906485B (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104761637B (zh) | 2006-03-31 | 2021-10-15 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| ES2595638T3 (es) | 2007-09-26 | 2017-01-02 | Chugai Seiyaku Kabushiki Kaisha | Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR |
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| EP2647706B1 (en) | 2010-11-30 | 2023-05-17 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| EP3973994A1 (en) | 2014-06-12 | 2022-03-30 | RA Pharmaceuticals, Inc. | Modulation of complement activity |
| KR101860280B1 (ko) | 2014-12-19 | 2018-05-21 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법 |
| BR112017011235A2 (pt) | 2014-12-19 | 2018-02-06 | Chugai Pharmaceutical Co Ltd | anticorpos anti-c5 e métodos de uso |
| US9937222B2 (en) | 2015-01-28 | 2018-04-10 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
| KR102605798B1 (ko) | 2015-02-05 | 2023-11-23 | 추가이 세이야쿠 가부시키가이샤 | 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용 |
| RU2733720C2 (ru) | 2015-12-16 | 2020-10-06 | Ра Фармасьютикалз, Инк. | Модуляторы активности комплемента |
| EP3494991A4 (en) | 2016-08-05 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES |
| KR20190093196A (ko) | 2016-12-07 | 2019-08-08 | 라 파마슈티컬스 인코포레이티드 | 보체 활성의 조절인자 |
| TWI826364B (zh) | 2017-04-03 | 2023-12-21 | 德商因夫萊亞斯有限公司 | 活性抑制劑於發炎性疾病之治療 |
| TWI786132B (zh) * | 2017-06-23 | 2022-12-11 | 德商因夫萊亞斯有限公司 | 活性抑制劑於發炎性疾病之治療 |
| WO2020112961A1 (en) | 2018-11-30 | 2020-06-04 | Chemocentryx, Inc. | Capsule formulations |
| TW202100179A (zh) * | 2019-03-08 | 2021-01-01 | 美商Ｒａ製藥公司 | 補體活性之調節劑 |
| IL312955B1 (en) | 2019-03-11 | 2026-01-01 | Inflarx Gmbh | Fused piperidinyl bicyclic compounds and related compounds as C5a receptor modulators |
| SG11202109837SA (en) * | 2019-04-24 | 2021-10-28 | Ra Pharmaceuticals Inc | Compositions and methods for modulating complement activity |
| JP2022535411A (ja) | 2019-06-04 | 2022-08-08 | ラ ファーマシューティカルズ インコーポレイテッド | 補体阻害剤による炎症性疾患治療 |
| TWI869528B (zh) | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| US20230050339A1 (en) * | 2020-02-18 | 2023-02-16 | Children's Hospital Medical Center | Compositions and methods for treating liver disease |
| TW202208427A (zh) | 2020-05-06 | 2022-03-01 | 德商因夫萊亞斯有限公司 | 人源化抗ｃ５ａ抗體 |
| WO2022033981A1 (en) * | 2020-08-12 | 2022-02-17 | Innate Pharma | Subcutaneous anti-c5ar antagonist treatment regimen with avdoralimab |
| JP7839157B2 (ja) | 2020-10-28 | 2026-04-01 | ケモセントリックス， インコーポレイテッド | 化膿性汗腺炎を処置する方法 |
| CN116529241A (zh) * | 2020-10-28 | 2023-08-01 | 坎莫森特里克斯公司 | 治疗化脓性汗腺炎的方法 |
| CA3173944A1 (en) | 2021-01-13 | 2022-07-21 | Visterra, Inc. | Humanized complement 5a receptor 1 antibodies and methods of use thereof |
| US12433657B2 (en) | 2022-01-04 | 2025-10-07 | B2M Medical, Inc. | Planar-shaped thermal balloon for mesenteric fat reduction |
| CN116036233A (zh) * | 2023-01-10 | 2023-05-02 | 中山大学附属第八医院（深圳福田） | 小分子化合物pmx 53在制备抑制血管钙化和血管纤维化药物中的应用 |
| JP2026510820A (ja) | 2023-03-16 | 2026-04-10 | アムジェン インコーポレイテッド | 化膿性汗腺炎診断用バイオマーカー |
| US12180274B2 (en) | 2023-05-26 | 2024-12-31 | Inflarx Gmbh | Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity |
| AU2024324780A1 (en) * | 2023-08-16 | 2026-02-05 | Inflarx Gmbh | Fused piperidinyl bicyclic and related compounds for use in the treatment of diseases |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4704355A (en) | 1985-03-27 | 1987-11-03 | New Horizons Diagnostics Corporation | Assay utilizing ATP encapsulated within liposome particles |
| WO1991004014A1 (en) | 1989-09-21 | 1991-04-04 | Synergen, Inc. | Method for transporting compositions across the blood brain barrier |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| AUPO755097A0 (en) | 1997-06-25 | 1997-07-17 | University Of Queensland, The | Receptor agonist and antagonist |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| AUPR833401A0 (en) | 2001-10-17 | 2001-11-08 | University Of Queensland, The | G protein-coupled receptor antagonists |
| AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| HUE038239T2 (hu) | 2004-02-12 | 2018-10-29 | Archemix Llc | Komplementrendszerrel összefüggõ rendellenességek kezelésében alkalmazható aptamer terapeutikumok |
| SG151283A1 (en) | 2004-03-26 | 2009-04-30 | Promics Pty Ltd | Treatment of neurological conditions using complement c5a receptor modulators |
| CN101553244B (zh) | 2006-07-21 | 2013-01-02 | 普罗米克斯有限公司 | 内膜增生和相关病状的治疗 |
| ES2570153T3 (es) * | 2006-08-22 | 2016-05-17 | Novo Nordisk As | Anticuerpos anti-C5aR con propiedades mejoradas |
| GB0617734D0 (en) | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
| WO2011056972A2 (en) * | 2009-11-04 | 2011-05-12 | Case Western Reserve University | Compositions and methods of treating a t cell mediated disorder |
| RS54998B1 (sr) | 2008-12-22 | 2016-11-30 | Chemocentryx Inc | Antagonisti c5ar |
| GB0905790D0 (en) | 2009-04-03 | 2009-05-20 | Alligator Bioscience Ab | Novel polypeptides and use thereof |
| EP2327725A1 (en) | 2009-11-26 | 2011-06-01 | InflaRx GmbH | Anti-C5a binding moieties with high blocking activity |
| RS56332B1 (sr) | 2010-06-24 | 2017-12-29 | Chemocentryx Inc | Antagonisti c5ar |
| DK3424953T3 (en) | 2011-06-06 | 2020-11-02 | Novo Nordisk As | Terapeutiske antistoffer |
| IL288931B2 (en) | 2013-03-14 | 2025-05-01 | Alnylam Pharmaceuticals Inc | Compositions comprising a complementary portion of C5 IRNA and methods of using them |
| JP2016523829A (ja) | 2013-05-08 | 2016-08-12 | ノヴォ ノルディスク アー／エス | Ｃ５ａｒアンタゴニストの使用 |
| CA2940319A1 (en) * | 2014-03-20 | 2015-09-24 | Inflarx Gmbh | Inhibitors of c5a for the treatment of viral pneumonia |
| WO2016044419A1 (en) | 2014-09-16 | 2016-03-24 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
| WO2016061066A1 (en) | 2014-10-15 | 2016-04-21 | Alexion Pharmaceuticals, Inc. | Methods of replicating a large scale eculizumab production cell culture |
| FR3030515B1 (fr) * | 2014-12-23 | 2017-01-20 | Galderma Res & Dev | Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines |
| EP3313437A1 (en) | 2015-06-26 | 2018-05-02 | Alexion Pharmaceuticals, Inc. | A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant |
| EP3439658B1 (en) | 2016-04-04 | 2021-11-24 | ChemoCentryx, Inc. | Soluble c5ar antagonists |
| TWI826364B (zh) * | 2017-04-03 | 2023-12-21 | 德商因夫萊亞斯有限公司 | 活性抑制劑於發炎性疾病之治療 |
| IL312955B1 (en) | 2019-03-11 | 2026-01-01 | Inflarx Gmbh | Fused piperidinyl bicyclic compounds and related compounds as C5a receptor modulators |
-
2018
- 2018-01-03 TW TW107100139A patent/TWI826364B/zh active
- 2018-01-03 TW TW112106878A patent/TW202348249A/zh unknown
- 2018-01-03 MX MX2019011825A patent/MX2019011825A/es unknown
- 2018-01-03 KR KR1020197031043A patent/KR20190138806A/ko not_active Ceased
- 2018-01-03 PL PL18701250T patent/PL3411400T3/pl unknown
- 2018-01-03 EP EP21197604.8A patent/EP3978523A1/en active Pending
- 2018-01-03 CA CA3058023A patent/CA3058023A1/en active Pending
- 2018-01-03 IL IL261809A patent/IL261809B2/en unknown
- 2018-01-03 JP JP2020502768A patent/JP7486415B2/ja active Active
- 2018-01-03 SG SG11201807998WA patent/SG11201807998WA/en unknown
- 2018-01-03 EP EP18701250.5A patent/EP3411400B1/en active Active
- 2018-01-03 DK DK18701250.5T patent/DK3411400T3/da active
- 2018-01-03 WO PCT/EP2018/050146 patent/WO2018184739A1/en not_active Ceased
- 2018-01-03 EP EP23179884.4A patent/EP4272821A3/en active Pending
- 2018-01-03 CN CN201880037003.9A patent/CN111108118A/zh active Pending
- 2018-01-03 ES ES18701250T patent/ES2893769T3/es active Active
- 2018-01-03 AU AU2018249310A patent/AU2018249310A1/en not_active Abandoned
- 2018-06-13 US US16/007,340 patent/US10376595B2/en active Active
- 2018-06-13 US US16/007,634 patent/US11273225B2/en active Active
- 2018-09-24 CL CL2018002698A patent/CL2018002698A1/es unknown
-
2019
- 2019-08-07 US US16/534,314 patent/US11464868B2/en active Active
- 2019-10-02 ZA ZA2019/06485A patent/ZA201906485B/en unknown
-
2020
- 2020-11-02 US US17/087,235 patent/US11890349B2/en active Active
-
2022
- 2022-08-10 JP JP2022127667A patent/JP2022176946A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US11464868B2 (en) | 2022-10-11 |
| TW201836641A (zh) | 2018-10-16 |
| WO2018184739A1 (en) | 2018-10-11 |
| KR20190138806A (ko) | 2019-12-16 |
| CL2018002698A1 (es) | 2018-12-07 |
| EP3411400B1 (en) | 2021-09-22 |
| TW202348249A (zh) | 2023-12-16 |
| CN111108118A (zh) | 2020-05-05 |
| US20200061202A1 (en) | 2020-02-27 |
| ES2893769T3 (es) | 2022-02-10 |
| US20210046191A1 (en) | 2021-02-18 |
| US10376595B2 (en) | 2019-08-13 |
| US20180282425A1 (en) | 2018-10-04 |
| US11890349B2 (en) | 2024-02-06 |
| JP2020515643A (ja) | 2020-05-28 |
| MX2019011825A (es) | 2020-12-11 |
| CA3058023A1 (en) | 2018-10-11 |
| EP4272821A3 (en) | 2024-01-03 |
| IL261809B1 (en) | 2023-12-01 |
| TWI826364B (zh) | 2023-12-21 |
| IL261809A (en) | 2018-11-29 |
| IL261809B2 (en) | 2024-04-01 |
| EP3411400A1 (en) | 2018-12-12 |
| US20180280530A1 (en) | 2018-10-04 |
| EP4272821A2 (en) | 2023-11-08 |
| DK3411400T3 (da) | 2021-10-11 |
| JP7486415B2 (ja) | 2024-05-17 |
| US11273225B2 (en) | 2022-03-15 |
| PL3411400T3 (pl) | 2021-12-20 |
| JP2022176946A (ja) | 2022-11-30 |
| SG11201807998WA (en) | 2018-12-28 |
| EP3978523A1 (en) | 2022-04-06 |
| ZA201906485B (en) | 2021-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11464868B2 (en) | Treatment of inflammatory diseases with inhibitors of C5A activity | |
| CA3066689C (en) | Treatment of inflammatory diseases with inhibitors of c5a activity | |
| US20230158060A1 (en) | Inhibitors of C5a for the Treatment of Corona Virus Infection | |
| HK40101423A (en) | Treatment of inflammatory diseases with inhibitors of c5a activity | |
| HK40070841A (en) | Treatment of inflammatory diseases with inhibitors of c5a activity | |
| EA043076B1 (ru) | Лечение воспалительных заболеваний с помощью ингибиторов активности c5a | |
| US20230272087A1 (en) | Method of treating or preventing acute respiratory distress syndrome | |
| US20240043562A1 (en) | Musk activation | |
| HK40000612B (en) | Treatment of inflammatory diseases with inhibitors of c5a activity | |
| EA049533B1 (ru) | ИНГИБИТОРЫ С5а ДЛЯ ЛЕЧЕНИЯ КОРОНАВИРУСНОЙ ИНФЕКЦИИ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |